120 related articles for article (PubMed ID: 2767108)
21. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
22. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
[TBL] [Abstract][Full Text] [Related]
23. Serum CA 125 levels in preoperative evaluation of pelvic masses.
Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
[TBL] [Abstract][Full Text] [Related]
24. [Combined CA-125 test and ultrasonography in the presurgical evaluation of ovarian mass].
Chiu SW; Ho SC; Hung YC; Lee YH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Aug; 7(8):429-34. PubMed ID: 1875465
[TBL] [Abstract][Full Text] [Related]
25. Ascites as a predictor of ovarian malignancy.
Shen-Gunther J; Mannel RS
Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
[TBL] [Abstract][Full Text] [Related]
26. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
27. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
Roman LD; Muderspach LI; Burnett AF; Morrow CP
J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
[TBL] [Abstract][Full Text] [Related]
28. What do CA 125 and other antigens tell us about ovarian cancer biology?
Welander CE
Acta Obstet Gynecol Scand Suppl; 1992; 155():85-93. PubMed ID: 1502896
[TBL] [Abstract][Full Text] [Related]
29. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
30. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
31. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
32. CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods.
Maggino T; Sopracordevole F; Matarese M; Di Pasquale C; Tambuscio G
Eur J Gynaecol Oncol; 1987; 8(6):590-5. PubMed ID: 3319631
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
O'Connell GJ; Ryan E; Murphy KJ; Prefontaine M
Obstet Gynecol; 1987 Dec; 70(6):930-2. PubMed ID: 3479735
[TBL] [Abstract][Full Text] [Related]
34. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
36. Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses.
Fioretti P; Gadducci A; Ferdeghini M; Bartolini T; Fontana V; Facchini V
Eur J Gynaecol Oncol; 1988; 9(4):291-4. PubMed ID: 3164674
[TBL] [Abstract][Full Text] [Related]
37. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.
Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC
Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):99-105. PubMed ID: 18995946
[TBL] [Abstract][Full Text] [Related]
39. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
40. The role of the CA 125 assay in the management of ovarian cancer.
Niloff JM
Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
